Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.
from Reuters: Health https://ift.tt/2MOwzOA
via
IFTTT
0 comments: